425 related articles for article (PubMed ID: 34541920)
1. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
[TBL] [Abstract][Full Text] [Related]
2. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
6. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
10. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
11. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
12. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
[TBL] [Abstract][Full Text] [Related]
13. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
[TBL] [Abstract][Full Text] [Related]
14. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
[TBL] [Abstract][Full Text] [Related]
15. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.
Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898
[TBL] [Abstract][Full Text] [Related]
16. Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center.
Stevens VM; Trujillo T; Mueller SW; MacLaren R; Reynolds PM; Kiser TH
Clin Appl Thromb Hemost; 2019; 25():1076029619896619. PubMed ID: 31876159
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
18. Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries.
Sadek E; Curtiss W; Andrews J; Hecht J
Emerg Med J; 2024 Feb; 41(3):162-167. PubMed ID: 38267194
[TBL] [Abstract][Full Text] [Related]
19. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
[TBL] [Abstract][Full Text] [Related]
20. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
